Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyAloha Care Antiemetics Coverage Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentAloha CarePolicy N/A

    Antiemetics for Oncology (NK1 RA, 5HT3 RA, combination)

    Customize your policy alerts

    Sign up for all Aloha Care policy alerts

    Know when Aloha Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior authorization, step therapy, and coverage criteria for antiemetic drugs used to prevent or treat chemotherapy-induced nausea and vomiting for Aloha Care members (Medicare and Medicaid specified in places). Affects providers requesting outpatient antiemetic drugs including injectable and oral NK1 RAs, 5HT3 RAs, and combination products.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAloha Care
    PolicyAntiemetics for Oncology (NK1 RA, 5HT3 RA, combination)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewNov 10, 2025
    Next Review DateNov 10, 2025
    Key ActionObtain prior authorization and document chemotherapy emetogenicity, trial history or physician attestation when requesting non-preferred or injectable antiemetic products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    up to 12 monthsApproval length for specified indications
    lists ~40Regimens enumerated
    11+HCPCS/J-codes listed
    Preferred / Non-preferredPreferred vs non-preferred
    NCCN & ASCOGuideline references

    Coverage Criteria for Antiemetics

    NK1 RA — Prevention criteria

    Covered when ALL of the following are met for prevention of chemotherapy-induced nausea and vomiting:

    NK1_RA_Prevention_High_Moderate: 1. The request is for prevention of chemotherapy-induced nausea and vomiting due to High Emetic Risk parenteral anticancer agents OR prevention due to Moderate Emetic Risk parenteral anticancer agents; AND 2. The medication will be used in combination with a 5HT3 RA; AND 3. At least one patient risk factor for CINV is present (younger age <55 years; female sex; little or no previous alcohol use; previous history of chemotherapy-induced nausea and vomiting; history of motion sickness or morning sickness during pregnancy; high anxiety).

    Approval length: as requested, up to 12 months; Line of Business: Medicare and Medicaid; Override Type: PA, QL

    5HT3 RA — Prevention and breakthrough treatment

    Covered when ONE of the following sets is met for prevention of chemotherapy-induced nausea and vomiting:

    5HT3_RA_Prevention_and_Breakthrough: A. Request is for prevention due to High Emetic Risk parenteral anticancer agents; OR B. Request is for prevention due to Moderate Emetic Risk parenteral anticancer agents when used in combination with an NK1 RA; OR C. Request is for treatment of breakthrough nausea and/or vomiting due to anticancer agent(s).

    Approval length: as requested, up to 12 months; Line of Business: Medicare and Medicaid; Override Type: PA, QL

    NK1 RA/5HT3 RA combination — Akynzeo criteria

    Covered when ALL of the following are met for Akynzeo:

    Akynzeo_Prevention_Criteria: 1. The request is for prevention of chemotherapy-induced nausea and vomiting due to Moderate Emetic Risk parenteral anticancer agents; AND 2. At least one patient risk factor for CINV is present (younger age <55 years; female sex; little or no previous alcohol use; previous history of CINV; history of motion sickness or morning sickness during pregnancy; high anxiety); OR 3. The request is for prevention due to High Emetic Risk parenteral anticancer agents.

    Approval length: as requested, up to 12 months; Line of Business: Medicare and Medicaid; Override Type: PA, QL. Akynzeo is an NK1 RA/5HT3 RA combination product (netupitant/palonosetron) indicated for prevention of acute and delayed nausea and vomiting per FDA labeling.

    Guideline-aligned coverage criteria

    Covered when regimen selection aligns with NCCN or ASCO guideline recommendations based on emetogenic risk and route of agent

    High emetic risk parenteral chemotherapy: For IV highly emetogenic chemotherapy (>90% emesis) provide multi-drug prophylaxis per guidelines including an NK1 RA (aprepitant/fosaprepitant/rolapitant/netupitant), a 5-HT3 RA (palonosetron preferred; granisetron or ondansetron options), and dexamethasone; guideline options include netupitant/palonosetron or fosnetupitant/palonosetron combinations and addition of olanzapine as recommended.

    NCCN and ASCO recommendations cited; use guideline-determined combinations for HEC.

    Moderate emetic risk parenteral chemotherapy: For IV moderate emetic risk (30-90%) provide a 5-HT3 RA plus dexamethasone; preference for palonosetron IV or granisetron extended-release injection when an NK1 RA is not used; NK1 RA plus 5-HT3 RA and dexamethasone is an alternative as per guidelines.

    Consider ASCO recommendation for carboplatin AUC ≥4 where NK1-containing 3-drug regimen is preferred.

    Low emetic risk parenteral chemotherapy: Recommend single-agent prophylaxis such as dexamethasone, metoclopramide, prochlorperazine, or an oral 5-HT3 RA; routine prophylaxis not recommended for minimal emetic risk.

    CMS does not have a National Coverage Determination (NCD), Local Coverage Determination (LCD) or Local Coverage Article (LCA) for several injectable antiemetic products referenced in this policy, including Aloxi® (palonosetron) injection, Akynzeo® (palonosetron/fosnetupitant) injection, Cinvanti® (aprepitant) injectable emulsion, Kytril® (granisetron) injection, Emend® (fosaprepitant) injection, and Sustol® (granisetron extended release) injection. Providers should review the applicable LCDs/LCAs and the Medicare Coverage Database for Hawaii-region determinations when making Medicare Part B coverage decisions.

    Oral antiemetics are excluded from coverage under this guideline when they are self-administered by the member outside of the infusion setting. Oral agents are included in coverage considerations only when administered prior to the chemotherapy infusion in the infusion setting; documentation of administration timing and appropriate HCPCS/Q-code billing is required.

    No additional explicit exclusions are specified in the cited sections of this policy.

    Antiemetic products that are not explicitly listed by name in this policy should be treated as non-preferred until the Optum Guideline Committee has reviewed and designated them. Coverage or prior authorization for non-listed products will require review per the committee's determinations.

    Use of experimental, investigational, or unproven antiemetic treatments may not be covered unless the member is participating in the Cancer Guidance Program (CGP) and the member-specific benefit plan or an applicable state mandate permits such coverage. Providers must consult the member's benefit document and any applicable state mandates when considering coverage for these therapies.

    The cited policy excerpts do not include any explicit statements labeling specific antiemetic uses or products as 'not medically necessary.'

    Emetogenic RiskAgents / Regimens (examples)
    {"text":"High (>90%):","status":""},{"text":"AC combination (any anthracycline + cyclophosphamide); Carboplatin AUC > 4; Carmustine > 250 mg/m2; Cisplatin; Cyclophosphamide > 1500 mg/m2; Dacarbazine; Datopotamab deruxtecan-dlnk; Doxorubicin > 60 mg/m2; Epirubicin > 90 mg/m2; Fam-trastuzumab deruxtecan‑nxki; Ifosfamide > 2 g/m2 per dose; Mechlorethamide; Melphalan > 140 mg/m2; Sacituzumab govitecan‑hziy; Streptozocin; Zolbetucimab‑clzb","status":""}
    {"text":"Moderate (30–90%):","status":""},{"text":"Aldesleukin > 12–15 million IU/m2 (or 600,000 IU/kg); Amifostine > 300 mg/m2; Bendamustine; Busulfan; Carboplatin AUC < 4; Carmustine < 250 mg/m2; Clofarabine; Cyclophosphamide < 1500 mg/m2; Cytarabine > 200 mg/m2; Dactinomycin; Daunorubicin; Dinutuximab; Doxorubicin < 60 mg/m2; Dual‑drug liposomal cytarabine+daunorubicin; Epirubicin < 90 mg/m2; Idarubicin; Ifosfamide; Iobenguane I‑131; Irinotecan (including liposomal); Lutetium Lu‑177 dotatate; Lurbinectedin; Melphalan < 140 mg/m2; Methotrexate > 250 mg/m2; Mirvetuximab soravtansine; Naxitamab","status":""}
    {"text":"Low (10–30%):","status":""},{"text":"Ado‑trastuzumab emtansine; Aldesleukin < 12 million IU/m2; Amifostine < 300 mg/m2; Amivantamab‑vmjw; Arsenic trioxide; Axicabtagene ciloleucel; Azacitidine; Belinostat; Brexucabtagene autoleucel; Brentuximab vedotin; Cabazitaxel; Carfilzomib; Ciltacabtagene autoleucel; Copanlisib; Cytarabine (low dose 100–200 mg/m2); Docetaxel; Liposomal doxorubicin; Elranatamab; Enfortumab vedotin; Epcoritamab; Eribulin; Etoposide; 5‑Fluorouracil; Floxuridine; Gemcitabine; Gemtuzumab ozogamicin; Idecabtagene vicleucel","status":""}
    {"text":"Minimal (<10%):","status":""},{"text":"(No specific minimal‑risk agents enumerated in cited chunks)","status":""}

    Billing and Diagnosis Codes

    HCPCS Codes listedHCPCS
    J1453Injection, fosaprepitant, 1 mg (EMEND) (preferred)
    J0185Injection, aprepitant, 1 mg (Cinvanti)
    J1434Injection, fosaprepitant (Focinvenz), 1 mg
    J1456Injection, fosaprepitant (teva), 1 mg
    J8670Rolapitant, oral, 1 mg (Varubi tablet)
    J1626Injection, granisetron hydrochloride, 100 mcg (Kytrel) (preferred)
    J2405Injection, ondansetron hydrochloride, per 1 mg (Zofran) (preferred)
    J1627Injection, granisetron, extended-release, 0.1 mg (Sustol)
    J2468Injection, palonosetron (avyxa), 25 mcg (preferred)
    J2469Injection, palonosetron HCl, 25 mcg (Aloxi) (preferred)
    1–10 of 12
    1/2
    Diagnosis Codes listedICD-10
    R11.0Nausea
    R11.10Vomiting, unspecified
    R11.2Nausea with vomiting, unspecified
    T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
    T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
    T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
    Z51.11Encounter for antineoplastic chemotherapy
    HCPCS / J / Q CodesHCPCS
    J0185Injection, aprepitant, 1 mg
    J1434Injection, fosaprepitant (focinvenz), 1 mg
    J1453Injection, fosaprepitant, 1 mg
    J1454Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
    J1456Injection, fosaprepitant (teva), 1 mg
    J1626Injection, granisetron hydrochloride, 100 mcg
    J1627Injection, granisetron, extended-release, 0.1 mg
    J2405Injection, ondansetron hydrochloride, per 1 mg
    J2468Injection, palonosetron (avyxa), 25 mcg
    J2469Injection, palonosetron HCl, 25 mcg
    1–10 of 15
    1/2
    Diagnosis CodesICD-10
    R11.0Nausea
    R11.10Vomiting, unspecified
    R11.2Nausea with vomiting, unspecified
    T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
    T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
    T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
    Z51.11Encounter for antineoplastic chemotherapy
    HCPCS/Drug codesHCPCS
    J1456Injection, fosaprepitant (teva), 1 mg
    J1626Injection, granisetron hydrochloride, 100 mcg
    J1627Injection, granisetron, extended-release, 0.1 mg
    J2405Injection, ondansetron hydrochloride, per 1 mg
    J2468Injection, palonosetron (avyxa), 25 mcg
    J2469Injection, palonosetron HCl, 25 mcg
    J8501Aprepitant, oral, 5 mg
    J8655Netupitant 300 mg and palonosetron 0.5 mg, oral
    J8670Rolapitant, oral, 1 mg
    Q0162Ondansetron 1 mg, oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen
    1–10 of 11
    1/2
    Diagnosis codesICD-10
    R11.0Nausea
    R11.10Vomiting, unspecified
    R11.2Nausea with vomiting, unspecified
    T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
    T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
    T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
    Z51.11Encounter for antineoplastic chemotherapy
    Carboplatin AUC threshold
    Carboplatin AUC thresholdAUC > 4 = high emetic risk; AUC < 4 = moderate emetic risk
    Source guidance contextListed among high- and moderate-emetic risk regimen enumerations used to select antiemetic prophylaxis per NCCN/ASCO
    Clinical implicationUse AUC >4 to qualify for higher-intensity prophylaxis (e.g., NK1 RA plus 5HT3 RA and dexamethasone)
    Cyclophosphamide dose threshold
    Cyclophosphamide dose threshold> 1500 mg/m2 = high emetic risk; < 1500 mg/m2 = moderate emetic risk

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior authorization required for many antiemetics

    Prior authorization (PA) is required for many antiemetic products; approvals are tied to diagnosis‑specific criteria (e.g., prevention of CINV for High or Moderate emetic risk parenteral chemotherapy) and may include quantity limits. Approval lengths up to 12 months may be granted for prevention of chemotherapy‑induced nausea and vomiting for Medicare and Medicaid members.

    • PA applies to NK1 RA and 5HT3 RA products when diagnostic criteria are met
    • Approval length: as requested, up to 12 months
    • Override types: PA and QL
    Prior Authorization

    PA may be required for J‑/Q‑coded products

    Prior authorization may be required per the member’s benefit document for injectable and specialty antiemetic products billed with the listed HCPCS J‑ and Q‑codes; providers must confirm PA requirements with the member‑specific benefit plan.

    • Examples of injectable/specialty codes: J0185, J1434, J1453, J1454, J1456, J1626, J1627, J2405, J2468, J2469, J8501, J8655, J8670, Q0162, Q0166

    Chemotherapy Regimens and Emetogenic Risk

    Emetogenic Risk CategoryRepresentative agents / regimens (used to select antiemetic prophylaxis)
    {"text":"High (>90% frequency of emesis)","status":""},{"text":"AC combination (any anthracycline + cyclophosphamide); Carboplatin AUC > 4; Cisplatin; Carmustine > 250 mg/m2; Cyclophosphamide > 1500 mg/m2; Doxorubicin > 60 mg/m2; Epirubicin > 90 mg/m2; Ifosfamide > 2 g/m2 per dose; Melphalan > 140 mg/m2; Dacarbazine; Mechlorethamide; Sacituzumab govitecan‑hziy; Streptozocin; Datopotamab deruxtecan‑dlnk; Fam‑trastuzumab deruxtecan‑nxki; Zolbetucimab‑clzb","status":""}
    {"text":"Moderate (30–90%)","status":""},{"text":"Aldesleukin > 12–15 million IU/m2 (or 600,000 IU/kg); Amifostine > 300 mg/m2; Bendamustine; Busulfan; Carboplatin AUC < 4; Carmustine < 250 mg/m2; Clofarabine; Cyclophosphamide < 1500 mg/m2; Cytarabine > 200 mg/m2; Dactinomycin; Daunorubicin; Dinutuximab; Doxorubicin < 60 mg/m2; Dual‑drug liposomal cytarabine+daunorubicin; Epirubicin < 90 mg/m2; Idarubicin; Ifosfamide; Iobenguane I‑131; Irinotecan (including liposomal); Lutetium Lu‑177 dotatate; Lurbinectedin; Melphalan < 140 mg/m2; Methotrexate > 250 mg/m2; Mirvetuximab soravtansine; Naxitamab‑gqgk","status":""}
    {"text":"Low (10–30%)","status":""},{"text":"Ado‑trastuzumab emtansine; Aldesleukin < 12 million IU/m2; Amifostine < 300 mg/m2; Amivantamab‑vmjw; Arsenic trioxide; Axicabtagene ciloleucel; Azacitidine; Belinostat; Brexucabtagene autoleucel; Brentuximab vedotin; Cabazitaxel; Carfilzomib; Ciltacabtagene autoleucel; Copanlisib; Cytarabine (low dose 100–200 mg/m2); Docetaxel; Liposomal doxorubicin; Elranatamab; Enfortumab vedotin; Epcoritamab; Eribulin; Etoposide; 5‑Fluorouracil; Floxuridine; Gemcitabine; Gemtuzumab ozogamicin; Idecabtagene vicleucel; Ixabepilone; Paclitaxel; Paclitaxel‑albumin; Pemetrexed; Pentostatin; Polatuzumab vedotin; Pralatrexate; Tafasitamab; Tagraxofusp; Talimogene laherparepvec; Tebentafusp; Thiotepa; Tisagenlecleucel; Tisotumab vedotin; Topotecan; Ziv‑aflibercept","status":""}
    {"text":"Minimal (<10%)","status":""},{"text":"(Minimal‑risk agents not specifically listed in the cited chunks)","status":""}

    First-line and Therapy Sequencing

    first-line

    First-line_FDA_labeled_prevention_indications: Use of FDA-labeled prevention indications for initial and repeat courses is supported for agents including Akynzeo (capsule or injection), Cinvanti (aprepitant emulsion), Emend (fosaprepitant/aprepitant), Varubi (rolapitant), Aloxi (palonosetron), Sustol (granisetron ER), Kytril (granisetron), and Zofran (ondansetron).

    This represents first-line/initial therapy placement; follow product labeling and guideline-based regimen selection for prophylaxis.

    Key Definitions and Drug Classes

    Neurokinin 1 Receptor Antagonist (NK1 RA)
    Agent examplesAprepitant and fosaprepitant (NK1 RAs) — aprepitant is a selective NK1 receptor antagonist; fosaprepitant is a prodrug rapidly converted to aprepitant.
    MechanismBlockade of substance P at NK1 receptors to prevent nausea and vomiting.
    Role in prophylaxisUsed as part of multi-drug prophylaxis for high-emetic-risk chemotherapy in combination with a 5HT3 RA and dexamethasone.
    5-Hydroxytryptamine Receptor Antagonist (5HT3 RA)
    Agent examplesPalonosetron, granisetron, and ondansetron (5HT3 RAs)
    MechanismBlock serotonin (5-HT3) activity centrally and in the GI tract to prevent nausea and vomiting.

    Injectable and Oral Antiemetic Codes

    HCPCS / J / Q CodesHCPCS
    J0185Injection, aprepitant, 1 mg
    J1434Injection, fosaprepitant (focinvenz), 1 mg
    J1453Injection, fosaprepitant, 1 mg
    J1454Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
    J1456Injection, fosaprepitant (teva), 1 mg
    J1626Injection, granisetron hydrochloride, 100 mcg
    J1627Injection, granisetron, extended-release, 0.1 mg
    J2405Injection, ondansetron hydrochloride, per 1 mg
    J2468Injection, palonosetron (avyxa), 25 mcg
    J2469Injection, palonosetron HCl, 25 mcg
    1–10 of 15
    1/2
    HCPCS/Drug codesHCPCS
    J1456Injection, fosaprepitant (teva), 1 mg
    J1626Injection, granisetron hydrochloride, 100 mcg
    J1627Injection, granisetron, extended-release, 0.1 mg
    J2405Injection, ondansetron hydrochloride, per 1 mg
    J2468Injection, palonosetron (avyxa), 25 mcg
    J2469Injection, palonosetron HCl, 25 mcg
    J8501Aprepitant, oral, 5 mg
    J8655Netupitant 300 mg and palonosetron 0.5 mg, oral
    J8670Rolapitant, oral, 1 mg
    Q0162Ondansetron 1 mg, oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen
    1–10 of 11
    1/2

    Clinical Background

    Chemotherapy- and radiation-related emesis can substantially reduce a patient’s quality of life and may negatively affect adherence to anticancer therapy. Risk of nausea and vomiting depends on the emetogenicity of the anticancer agent (including dose and route), radiation target, and patient-specific factors such as younger age, female sex, low alcohol use, prior history of chemotherapy-induced nausea and vomiting, history of motion sickness or morning sickness during pregnancy, and high anxiety. These factors are used to guide prophylaxis intensity and regimen selection per guideline recommendations.

    Policy Revision History

    2026-01-01Policy effective dateLatest

    Policy effective date set to 2026-01-01 per document header metadata.

    2025-11-10Last review

    Policy last reviewed on 2025-11-10 as shown in document header and source chunks.

    2025-09-11Content update
    Policy Summary
    PayerAloha Care
    PolicyAntiemetics for Oncology (NK1 RA, 5HT3 RA, combination)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewNov 10, 2025
    Next Review DateNov 10, 2025
    Key ActionObtain prior authorization and document chemotherapy emetogenicity, trial history or physician attestation when requesting non-preferred or injectable antiemetic products.
    SourceLink
    On This Page
    Coverage Criteria for AntiemeticsBilling and Diagnosis CodesPrior Authorization, Step Therapy, and DocumentationChemotherapy Regimens and Emetogenic RiskFirst-line and Therapy SequencingKey Definitions and Drug ClassesInjectable and Oral Antiemetic CodesClinical BackgroundPolicy Revision History

    Per NCCN/ASCO guidance.

    Oral antineoplastic agents: For oral agents with moderate-high emetic risk (≥30%) recommend a 5-HT3 RA; for low-minimal risk recommend initial as-needed treatment (metoclopramide, prochlorperazine, or oral 5-HT3 RA) with escalation guided by symptoms.

    Follow NCCN categories for oral agents.

    Breakthrough nausea/vomiting: If breakthrough occurs despite optimal prophylaxis, escalate to a higher-level regimen for subsequent cycles; consider adding olanzapine if not used previously, or add a drug of a different class (NK1 RA, benzodiazepine, dopamine antagonist, dronabinol/nabilone) per ASCO guidance.

    Document reassessment and change in regimen per guidelines.

    Source guidance contextCyclophosphamide dose cutoffs are included in the policy's enumerated high- and moderate-emetic risk regimen lists
    Clinical implicationCyclophosphamide >1500 mg/m2 supports selection of high-emetic risk prophylaxis regimens
  1. Confirm PA via member benefit document prior to administration/billing
  2. Note

    HCPCS / J / Q codes listed (reference only)

    The policy lists specific HCPCS, J‑, and Q‑codes for injectable and oral antiemetics to be used for billing and prior authorization reference; the chunks here enumerate those codes but do not specify PA applicability.

    • Included procedure codes: J1456, J1626, J1627, J2405, J2468, J2469, J8501, J8655, J8670, Q0162, Q0166
    • Diagnosis codes listed for claims: R11.0, R11.10, R11.2, T45.1X5A/D/S, Z51.11
    Step Therapy

    Trial of preferred NK1 RA/5HT3 RA required before non‑preferred agents

    A trial of adequate dose and duration of a preferred NK1 RA or preferred 5HT3 RA is required before a non‑preferred NK1 RA, 5HT3 RA, or NK1/5HT3 combination product will be approved, unless alternative attestation criteria are met.

    • Required: history of trial to a preferred product with minimal clinical response documented
    • Alternative: physician attestation of expected superiority or documentation of intolerance/contraindication to preferred agent
    Note

    No explicit step sequence — follow NCCN/ASCO guidance

    The policy does not provide a rigid sequencing algorithm; instead it references guideline‑based regimen selection (NCCN/ASCO) and notes that oral agents are included only when administered prior to infusion.

    • Follow NCCN/ASCO regimen recommendations based on emetogenic risk and route
    • Oral antiemetics are only included when given prior to chemotherapy infusion (not when self‑administered outside infusion)
    Note

    No additional step therapy requirements specified

    These policy chunks do not specify additional step therapy requirements beyond the trial/attestation language already provided.

    Documentation Required

    Physician attestation and prior trial documentation required for non‑preferred agents

    When requesting a non‑preferred NK1 RA, 5HT3 RA, or combination product, the physician must attest to either prior trial and inadequate response to a preferred agent or document intolerance/contraindication and state that the same issue is not expected with the requested non‑preferred product.

    • Physician attestation must state clinical rationale (superiority, intolerance, or contraindication)
    • Document prior trial of adequate dose/duration if applicable
    Documentation Required

    Submit clinical documentation supporting indication and risk factors

    Documentation submitted for diagnosis‑specific approvals must support the emetogenicity of the chemotherapy (High or Moderate risk), indicate combination use when required (e.g., NK1 plus 5HT3 RA), and include patient risk factors when applicable (younger age, female sex, low alcohol use, prior CINV, motion/morning sickness, high anxiety).

    • Show chemotherapy emetogenicity (High or Moderate) used to justify antiemetic selection
    • Document combination use (NK1 RA with 5HT3 RA) when required by criteria
    • Include relevant patient risk factors for CINV
    Billing Rule

    Document administration route and timing (oral agents only if given before infusion)

    Document the administration route and timing relative to chemotherapy; oral antiemetics are only included when administered prior to infusion and are not covered when self‑administered outside the infusion setting.

    • Specify route (IV, oral) and timing relative to chemotherapy on documentation/claim
    • Oral agents are included only if given prior to the chemotherapy infusion
    Billing Rule

    Include listed HCPCS/J/Q codes and an associated diagnosis code on claims

    Providers should bill using the HCPCS/J‑ and Q‑codes listed in the guideline and include an associated diagnosis code such as R11.0, R11.10, R11.2, T45.1X5A/D/S, or Z51.11 to reflect nausea/vomiting or an encounter for antineoplastic chemotherapy.

    • Use applicable HCPCS/J/Q procedure code for the antiemetic administered
    • Include supporting diagnosis code (e.g., Z51.11 for chemotherapy encounter) on the claim
    Denial Risk

    Missing step therapy or attestation risks denial or delay

    Failure to meet the step therapy criteria — for example, no documented trial of a preferred product or lack of physician attestation of superiority/intolerance — may result in denial or delay of coverage for non‑preferred NK1 RA, 5HT3 RA, or combination products.

    • Denial risk if prior trial or attestation documentation is missing
    • May cause coverage delay while documentation is obtained or reviewed
    Denial Risk

    Coverage constrained by member benefit or state mandates

    Coverage may be denied if the member‑specific benefit plan document or applicable state mandates do not authorize experimental, investigational, or otherwise unproven treatments; consult the member’s benefit document.

    • Benefit plan or state mandates may supersede policy language
    • CGP participants may have different coverage for investigational/unproven treatments — verify member benefit
    Note

    Use listed HCPCS and diagnosis codes to support claims and PAs

    The policy lists HCPCS and diagnosis codes that are relevant to billing and claims support; use these listed codes to substantiate claims and prior authorization requests where applicable.

    • Reference the guideline’s HCPCS/J/Q listings when preparing claims and PAs
    • Inclusion of a code in the guideline is for reference and does not guarantee reimbursement — confirm with benefit plan
    Clinical useEmployed for acute and delayed emesis prevention; palonosetron preferred in some high-risk regimens per guidelines.
    NK1 RA/5HT3 RA combination (Akynzeo)
    DefinitionAkynzeo is a fixed combination of an NK1 receptor antagonist (netupitant or fosnetupitant) and the 5-HT3 receptor antagonist palonosetron.
    Formulations citedAvailable as oral and injectable combination formulations used for prevention of chemotherapy-induced nausea and vomiting.
    Role in prophylaxisListed among guideline-supported combination options for high- and moderate-emetic-risk chemotherapy regimens.
    Acute Emesis
    TimeframeAcute Emesis: Nausea and/or vomiting that occurs within a few minutes to several hours after administration of anticancer agents and commonly resolves within the first 24 hours.
    Clinical relevanceDefines the period addressed by 'acute' antiemetic prophylaxis and informs timing of administered agents.
    Implication for coding/documentationDocument timing of symptoms relative to chemotherapy to support appropriate prophylaxis or treatment claims.
    Delayed Emesis
    TimeframeDelayed Emesis: Nausea and/or vomiting that occurs more than 24 hours after anticancer agent administration.
    Clinical relevanceSpecifies the period targeted by delayed-emesis prophylaxis and follow-up management (e.g., multi-day regimens or agents with delayed activity).
    Implication for regimen selectionDelayed emesis risk influences choice and duration of prophylactic agents (e.g., inclusion of NK1 RA, dexamethasone, or olanzapine).
    Emetogenic risk levels
    High emetic risk> 90% frequency of emesis
    Moderate emetic risk30-90% frequency of emesis
    Low emetic risk10-30% frequency of emesis
    Minimal emetic risk< 10% frequency of emesis
    Encounter for antineoplastic chemotherapy (Z51.11)
    ICD-10 codeZ51.11 — Encounter for antineoplastic chemotherapy
    Use caseUse on claims to indicate a patient encounter for chemotherapy when billing for prophylactic or treatment antiemetic services.
    Related diagnosis codesAlso consider R11.0, R11.10, R11.2, and T45.1X5A/D/S when coding for nausea/vomiting or adverse effects of antineoplastic drugs.

    Document updated on 2025-09-11 per review history noted in the source.